Additionally, we reported that an epigenetic small-molecule inhibitor of HDACs, PCI-24781, could target RGS2 to reduce cell proliferation, metastasis, and differentiation, resulting in cell death during breast cancer progression (39). This evidence concerns the gene RGS2 and breast carcinoma.